tickmark
Sign in

Tickdelta is free for now. Sign up and get Pro free

← Screener

CORCencora

Health care · Drug Wholesale · NYSE

Cencora is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. 10-K, Item 1

Employees
51,000
Headquarters
Conshohocken, PA
CEO
Robert P. Mauch
Next results
around Feb 3, 2027
Compare with peers → Embed
RevenueFY2016–25 $321.3B+9.3% Highest in 10 years 10-K FY2025 · XBRL Net incomeFY2016–25 $1.6B+3.0% FY2024: $1.5B 10-K FY2025 · XBRL Free cash flowFY2016–25 $3.2B+7.0% FY2024: $3.0B 10-K FY2025 · XBRL Operating marginFY2016–25 0.8%+0.1 pts 1.0% in FY2016 10-K FY2025 · XBRL

What changed

10-K filed Nov 25, 2025 against Nov 26, 2024
AreaWhat changedSource
Risk factors14 new paragraphs, nothing like them in the previous 10-K10-K Item 1A
Accounting checks11 other checks clear10-K · XBRL
InsidersNo open-market buys in the last 90 daysForm 4
Filings3 in the last 30 daysEDGAR

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

What's new, in their words

10-K filed Nov 25, 2025

Paragraphs in Risk Factors that were not in the 10-K filed 2024-11-26. Quoted as filed.

  1. On August 28, 2025, Sycamore Partners, a private equity firm, acquired Walgreens Boots Alliance, Inc. (“WBA”). We have a distribution agreement in the U.S. pursuant to which we distribute pharmaceuticals to Walgreens pharmacies as well as a generics purchasing services arrangement under which Walgreens Boots Alliance Development GmbH…
    10-K, Item 1A
All 14 new paragraphs →

Accounting checks

latest 10-K

11 of 11 clear 0 worth a look. Checks, not verdicts.

  • ✓
    Receivables +5.7% vs revenue +9.3% (-3.6 pts)
  • ✓
    Cash from operations $3.9B vs net income $1.6B (FY ending 2025-09-30)
  • ✓
    Inventory +7.9% vs revenue +9.3% (-1.5 pts)
  • ✓
    Same auditor in both 10-Ks: Ernst & Young LLP
  • ✓
    No statement of substantial doubt about going concern
  • ✓
    No 8-K item 4.02 in the last 2 years
  • ✓
    No NT 10-K or NT 10-Q in the last 2 years
  • ✓
    The same matters as last year: Legal Matters and Contingencies - Opioid Lawsuits and Investigations; Goodwill Impairment Evaluation of the PharmaLex Reporting Unit
  • ✓
    No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • ✓
    No 8-K item 2.06 in the last 2 years
  • ✓
    No 8-K item 1.03 in the last 2 years
How each check works, with sources →

In the last 30 days

All filings →

Work on COR in a spreadsheet: Excel workbook (a sheet per section, ten years by column, charts, links to the filings) · CSV. For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/COR/export.csv") into a cell.